203 related articles for article (PubMed ID: 21464038)
1. Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice.
Mackenzie GG; Ouyang N; Xie G; Vrankova K; Huang L; Sun Y; Komninou D; Kopelovich L; Rigas B
Cancer Prev Res (Phila); 2011 Jul; 4(7):1052-60. PubMed ID: 21464038
[TBL] [Abstract][Full Text] [Related]
2. Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice.
Mackenzie GG; Sun Y; Huang L; Xie G; Ouyang N; Gupta RC; Johnson F; Komninou D; Kopelovich L; Rigas B
Gastroenterology; 2010 Oct; 139(4):1320-32. PubMed ID: 20600034
[TBL] [Abstract][Full Text] [Related]
3. Phospho-sulindac (OXT-922) inhibits the growth of human colon cancer cell lines: a redox/polyamine-dependent effect.
Huang L; Zhu C; Sun Y; Xie G; Mackenzie GG; Qiao G; Komninou D; Rigas B
Carcinogenesis; 2010 Nov; 31(11):1982-90. PubMed ID: 20627873
[TBL] [Abstract][Full Text] [Related]
4. Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma.
Thompson PA; Wertheim BC; Zell JA; Chen WP; McLaren CE; LaFleur BJ; Meyskens FL; Gerner EW
Gastroenterology; 2010 Sep; 139(3):797-805, 805.e1. PubMed ID: 20538001
[TBL] [Abstract][Full Text] [Related]
5. Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention.
Meyskens FL; Gerner EW; Emerson S; Pelot D; Durbin T; Doyle K; Lagerberg W
J Natl Cancer Inst; 1998 Aug; 90(16):1212-8. PubMed ID: 9719082
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
[TBL] [Abstract][Full Text] [Related]
7. The metabolism and pharmacokinetics of phospho-sulindac (OXT-328) and the effect of difluoromethylornithine.
Xie G; Nie T; Mackenzie GG; Sun Y; Huang L; Ouyang N; Alston N; Zhu C; Murray OT; Constantinides PP; Kopelovich L; Rigas B
Br J Pharmacol; 2012 Apr; 165(7):2152-66. PubMed ID: 21955327
[TBL] [Abstract][Full Text] [Related]
8. Influence of K-ras activation on the survival responses of Caco-2 cells to the chemopreventive agents sulindac and difluoromethylornithine.
Lawson KR; Ignatenko NA; Piazza GA; Cui H; Gerner EW
Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1155-62. PubMed ID: 11097222
[TBL] [Abstract][Full Text] [Related]
9. Effects of alpha-difluoromethylornithine and recombinant interferon-alpha 2 on the growth of a human renal cell adenocarcinoma xenograft in nude mice.
Heston WD; Fleischmann J; Tackett RE; Ratliff TL
Cancer Res; 1984 Aug; 44(8):3220-5. PubMed ID: 6430546
[TBL] [Abstract][Full Text] [Related]
10. Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine.
Carbone PP; Douglas JA; Larson PO; Verma AK; Blair IA; Pomplun M; Tutsch KD
Cancer Epidemiol Biomarkers Prev; 1998 Oct; 7(10):907-12. PubMed ID: 9796636
[TBL] [Abstract][Full Text] [Related]
11. 2-Deoxy-D-glucose inhibits the antitumor effects of alpha-difluoromethylornithine on the growth of colon cancer in vivo.
Saydjari R; Upp JR; Alexander RW; Barranco SC; Townsend CM; Thompson JC
Invest New Drugs; 1989 Jul; 7(2-3):131-8. PubMed ID: 2507471
[TBL] [Abstract][Full Text] [Related]
12. Chemoprevention of Colon Cancer by DFMO, Sulindac, and NO-Sulindac Administered Individually or in Combinations in F344 Rats.
Madka V; Patlolla JMR; Venkatachalam K; Zhang Y; Pathuri G; Stratton N; Lightfoot S; Janakiram NB; Mohammed A; Rao CV
Cancers (Basel); 2023 Aug; 15(15):. PubMed ID: 37568816
[TBL] [Abstract][Full Text] [Related]
13. Selenium and difluoromethylornithine additively inhibit DMH-induced distal colon tumor formation in rats fed a fiber-free diet.
McGarrity TJ; Peiffer LP
Carcinogenesis; 1993 Nov; 14(11):2335-40. PubMed ID: 8242864
[TBL] [Abstract][Full Text] [Related]
14. Rationale for, and design of, a clinical trial targeting polyamine metabolism for colon cancer chemoprevention.
Gerner EW; Meyskens FL; Goldschmid S; Lance P; Pelot D
Amino Acids; 2007 Aug; 33(2):189-95. PubMed ID: 17396214
[TBL] [Abstract][Full Text] [Related]
15. Development of difluoromethylornithine (DFMO) as a chemoprevention agent.
Meyskens FL; Gerner EW
Clin Cancer Res; 1999 May; 5(5):945-51. PubMed ID: 10353725
[TBL] [Abstract][Full Text] [Related]
16. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet.
Reddy BS; Nayini J; Tokumo K; Rigotty J; Zang E; Kelloff G
Cancer Res; 1990 May; 50(9):2562-8. PubMed ID: 2109653
[TBL] [Abstract][Full Text] [Related]
17. Differential sensitivity of various human tumors to inhibition of polyamine biosynthesis in vivo.
Saydjari R; Alexander RW; Upp JR; Barranco SC; Townsend CM; Thompson JC
Int J Cancer; 1991 Jan; 47(1):44-8. PubMed ID: 1985877
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effects of two polyamine antimetabolites combined with mitomycin C on human stomach cancer cells xenotransplanted into nude mice.
Fujimoto S; Igarashi K; Shrestha RD; Miyazaki M; Okui K
Int J Cancer; 1985 Jun; 35(6):821-5. PubMed ID: 3924844
[TBL] [Abstract][Full Text] [Related]
19. alpha-difluoromethylornithine induces apoptosis as well as anti-angiogenesis in the inhibition of tumor growth and metastasis in a human gastric cancer model.
Takahashi Y; Mai M; Nishioka K
Int J Cancer; 2000 Jan; 85(2):243-7. PubMed ID: 10629084
[TBL] [Abstract][Full Text] [Related]
20. Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis.
Ignatenko NA; Besselsen DG; Stringer DE; Blohm-Mangone KA; Cui H; Gerner EW
Nutr Cancer; 2008; 60 Suppl 1():30-5. PubMed ID: 19003578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
